Are there new treatments or clinical trials for removing amyloid deposits from the heart in wild-type amyloidosis?
There's promising research on a drug called ALXN2220 that may actually remove amyloid deposits already built up in the heart. This is exciting because current FDA-approved medications like tafamidis can slow Show Full Answer
Are there new treatments or clinical trials for removing amyloid deposits from the heart in wild-type amyloidosis?
There's promising research on a drug called ALXN2220 that may actually remove amyloid deposits already built up in the heart. This is exciting because current FDA-approved medications like tafamidis can slow down wild-type ATTR amyloidosis but can't clear out the proteins already deposited.
ALXN2220 has received fast-track status from the FDA, which speeds up the approval process. Early trials with 40 participants showed it might reverse heart damage by clearing deposits. However, larger studies are still needed to confirm its effectiveness.
In the meantime, several medications are approved to help prevent further buildup in wild-type ATTR affecting the heart:
* Acoramidis (Attruby)
* Tafamidis (Vyndamax)
* Tafamidis meglumine (Vyndaqel)
* Vutrisiran (Amvuttra)
Other drugs like eplontersen, inotersen, and patisiran are being studied in clinical trials for wild-type ATTR amyloidosis.
Work with your cardiologist to discuss whether you might be a candidate for any clinical trials or these newer treatment options based on your specific situation.
December 4, 2025
Join
Your Privacy Choices
